Comparing an AI test to a 21-gene assay for premenopausal node-positive HR+/HER2- breast cancer
Elayoubi, J.; Tang, C.; Ruddy, K. J.; Choucair, K.; Kalinsky, K.; Pogoda, K.; Esteva, F. J.; Abdelsattar, J. M.; Borges, V. F.; Zeng, K.; Cappadona, J.; Machura, B.; Biswas, D.; Geras, K. J.; Witowski, J.
Show abstract
Recurrence scores based on a 21-gene assay are clinically useful for predicting prognosis and chemotherapy benefit in postmenopausal node-positive breast cancer patients, but its performance in premenopausal patients is inconsistent. Here, we evaluated Ataraxis Breast RISK (ATX), an AI test that predicts recurrence risk, and compared it with the genomic assay. ATX identified high risk patients misclassified as low risk by the genomic assay and therefore may refine selection of patients for adjuvant chemotherapy.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.